Association of Far-Infrared Radiation Therapy and Ankle-Brachial Index of Patients on Hemodialysis with Peripheral Artery Occlusive Disease

August 13, 2017

Abstract

Background and Aim

The ankle-brachial index (ABI) is recognized to be a good marker for

atherosclerosis, and is useful in the diagnosis of peripheral artery occlusive disease (PAOD) which

is prevalent among patients on hemodialysis (HD).

Methods

This randomized trial aimed to evaluate the effect of far-infrared radiation (FIR) therapy on ABI in HD patients with PAOD. PAOD was defined as patients with ABI < 0.95. One hundred and eight HD patients were enrolled, including 50 in the control group and 58 in the FIR group. A WS TY101 FIR emitter was applied for 40 minutes during each HD session, three times per week for six months. The ABI was measured before and after the FIR therapy.

Results

Regardless of FIR therapy, the bilateral ABI decreased (in the FIR group, left: 0.88±0.22 to 0.85±0.24, p = 0.188; right: 0.92±0.20 to 0.90±0.23, p = 0.372; in control group, left: 0.91±0.23 to 0.88±0.21, p = 0144; right: 0.93±0.17 to 0.89±0.21, p = 0.082). Multivariate logistic analysis of the FIR group revealed that high uric acid (odds ratio [OR]: 2.335; 95% confidence interval [CI]: 1.117-4.882; p=0.024) and aspirin use (OR: 16.463; 95% CI: 1.787-151.638; p=0.013) were independently associated with increased bilateral ABI after FIR therapy.

Conclusions

This study demonstrates that ABI is not increased after FIR therapy in HD patients with PAOD. However, in the FIR group, patients with higher uric acid level or those who used aspirin have increased bilateral ABI after FIR therapy.

-Int. J. Med. Sci. 2016, 13(12): 970-976

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
August 19, 2026
A new study published in Cells has provided further insight into the molecular responses of arterial endothelial cells following far-infrared (FIR) irradiation.  The study, conducted by researchers from Gunma Paz University, Japan, investigated the effects of FIR on human femoral artery endothelial cells (HFAECs) using an integrated multi-omics approach combining transcriptomics, proteomics, and phosphoproteomics. FIR irradiation was delivered using the WSTM TY101F far-infrared therapy unit manufactured by WS Far Infrared Medical Technology.
FIRAPY at MEDICA 2026 | Innovative Care for Dialysis Patients
August 19, 2026
Meet FIRAPY at MEDICA 2026 in Düsseldorf, November 16–19. Visit Hall 16, Booth B03-2 to explore innovative far infrared therapy for dialysis patient care.
More Posts